2. Platelet count ≥ 50,000/μL, with or without transfusion support; platelet count < 50,000/μL but ≥ 20,000/μL, with or without transfusion support, is permissible if the patient has not had Grade ≥ 2 bleeding in the prior 6 months (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version 4.03).